NASDAQ:SPRO Spero Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spero Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.39 -0.04 (-0.42 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$9.26Now: $9.39▼$9.7650-Day Range$8.96MA: $11.25▼$13.2052-Week Range$5.25Now: $9.39▼$14.48Volume179,741 shsAverage Volume193,153 shsMarket Capitalization$198.63 millionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSpero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.33, Spero Therapeutics has a forecasted upside of 159.1% from its current price of $9.39.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesSpero Therapeutics has received 173 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSpero Therapeutics has received 150 “underperform” votes. (Add your “underperform” vote.)Community SentimentSpero Therapeutics has received 53.56% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote “Outperform” if you believe SPRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,587.00 in company stock.Percentage Held by InsidersOnly 18.34% of the stock of Spero Therapeutics is held by insiders.Percentage Held by Institutions50.40% of the stock of Spero Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spero Therapeutics are expected to grow in the coming year, from ($3.67) to ($3.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO Previous Symbol CUSIPN/A CIK1701108 Websperotherapeutics.com Phone857-242-1600Debt Debt-to-Equity Ratio0.06 Current Ratio4.49 Quick Ratio4.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.15 million Price / Sales10.94 Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book2.41Profitability EPS (Most Recent Fiscal Year)($3.35) Net Income$-60,920,000.00 Net Margins-715.20% Return on Equity-103.39% Return on Assets-78.57%Miscellaneous Employees57 Outstanding Shares21,153,000Market Cap$198.63 million Next Earnings Date11/2/2020 (Estimated) OptionableOptionable $9.39 -0.04 (-0.42 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SPRO News and Ratings via Email Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions How has Spero Therapeutics' stock been impacted by COVID-19? Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SPRO shares have increased by 21.2% and is now trading at $9.39. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Spero Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spero Therapeutics. When is Spero Therapeutics' next earnings date? Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020. View our earnings forecast for Spero Therapeutics. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics Inc (NASDAQ:SPRO) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.17) by $0.32. The company earned $1.73 million during the quarter, compared to analyst estimates of $2.95 million. Spero Therapeutics had a negative net margin of 715.20% and a negative return on equity of 103.39%. View Spero Therapeutics' earnings history. What price target have analysts set for SPRO? 5 Wall Street analysts have issued 1 year target prices for Spero Therapeutics' shares. Their forecasts range from $20.00 to $28.00. On average, they anticipate Spero Therapeutics' stock price to reach $24.33 in the next twelve months. This suggests a possible upside of 159.1% from the stock's current price. View analysts' price targets for Spero Therapeutics. Are investors shorting Spero Therapeutics? Spero Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,270,000 shares, an increase of 18.7% from the August 15th total of 1,070,000 shares. Based on an average daily trading volume, of 240,900 shares, the short-interest ratio is presently 5.3 days. Currently, 8.5% of the shares of the company are short sold. View Spero Therapeutics' Short Interest. Who are some of Spero Therapeutics' key competitors? Some companies that are related to Spero Therapeutics include Akouos (AKUS), Morphic (MORF), Frequency Therapeutics (FREQ), Protagonist Therapeutics (PTGX), Phibro Animal Health (PAHC), Endo International (ENDP), RAPT Therapeutics (RAPT), Emisphere Technologies (EMIS), VBI Vaccines (VBIV), Provention Bio (PRVB), Kadmon (KDMN), Cara Therapeutics (CARA), Spectrum Pharmaceuticals (SPPI), DiaMedica Therapeutics (DMCAF) and Collegium Pharmaceutical (COLL). View all competitors. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Kadmon (KDMN), Editas Medicine (EDIT), Aldeyra Therapeutics (aldx), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN). Who are Spero Therapeutics' key executives? Spero Therapeutics' management team includes the following people: Dr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 39, Pay $747.88k)Ms. Cristina Larkin, Chief Operating Officer (Age 50, Pay $552.96k)Dr. David A. Melnick M.D., Chief Medical Officer (Age 68, Pay $545.96k)Mr. Stephen J. DiPalma M.B.A., Interim CFO & Treasurer (Age 61)Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 66) When did Spero Therapeutics IPO? (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. What is Spero Therapeutics' stock symbol? Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO." Who are Spero Therapeutics' major shareholders? Spero Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Artal Group S.A. (2.58%), BVF Inc. IL (2.30%), AWM Investment Company Inc. (1.15%), Jacobs Levy Equity Management Inc. (0.88%), Russell Investments Group Ltd. (0.45%) and Nuveen Asset Management LLC (0.31%). View institutional ownership trends for Spero Therapeutics. Which major investors are selling Spero Therapeutics stock? SPRO stock was sold by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., BVF Inc. IL, FMR LLC, FMR LLC, Artal Group S.A., UBS Group AG, and Stifel Financial Corp. View insider buying and selling activity for Spero Therapeutics. Which major investors are buying Spero Therapeutics stock? SPRO stock was purchased by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Russell Investments Group Ltd., Bessemer Group Inc., California Public Employees Retirement System, Goldman Sachs Group Inc., Nuveen Asset Management LLC, Two Sigma Advisers LP, and Radnor Capital Management LLC. View insider buying and selling activity for Spero Therapeutics. How do I buy shares of Spero Therapeutics? Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Spero Therapeutics' stock price today? One share of SPRO stock can currently be purchased for approximately $9.39. How big of a company is Spero Therapeutics? Spero Therapeutics has a market capitalization of $198.63 million and generates $18.15 million in revenue each year. The company earns $-60,920,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Spero Therapeutics employs 57 workers across the globe. What is Spero Therapeutics' official website? The official website for Spero Therapeutics is sperotherapeutics.com. How can I contact Spero Therapeutics? Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
